Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
• To describe the safety profiles (injection site reactions and systemic events) during the 21 days following each vaccination in subjects receiving the D0-D21 and the D0-D42 vaccination schedules, and 14 days and 21 days after Vac1 and Vac2, respectively, in subjects aged 9 to 17 years receiving the D0-D14 vaccination schedule • To describe the immune response 21 days after each vaccination in subjects receiving the D0-D21 vaccination schedule
Critère d'inclusion
- Vaccination of healthy children aged 6 months to 17 years with pandemic Flu H5N1 vaccine (30µgHA+aluminum hydroxide vaccine)